These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 35145275)

  • 21. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.
    Milder TY; Stocker SL; Samocha-Bonet D; Day RO; Greenfield JR
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1481-1490. PubMed ID: 31377891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease.
    Chan JSK; Perone F; Bayatpoor Y; Tse G; Harky A
    Expert Opin Pharmacother; 2023 Jun; 24(8):935-945. PubMed ID: 37070470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease.
    Scheen AJ; Delanaye P
    Expert Rev Endocrinol Metab; 2022 Jan; 17(1):35-46. PubMed ID: 34908510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
    Mende CW
    Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can chronic kidney disease lead to chronic heart failure, and does worsening chronic heart failure lead to chronic kidney disease progression.
    Leon SJ; Tangri N
    Curr Opin Nephrol Hypertens; 2022 Mar; 31(2):205-211. PubMed ID: 34954720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.
    Johansen ME; Argyropoulos C
    Clin Cardiol; 2020 Dec; 43(12):1376-1387. PubMed ID: 33165977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review.
    Scheen AJ
    Expert Rev Endocrinol Metab; 2023; 18(4):271-282. PubMed ID: 37154218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology.
    Hong T; Su Q; Li X; Shan Z; Chen L; Peng Y; Chen L; Yan L; Bao Y; Lyu Z; Shi L; Wang W; Guo L; Ning G; Mu Y; Zhu D
    Diabetes Metab Res Rev; 2021 May; 37(4):e3416. PubMed ID: 33120435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Vaduganathan M; Januzzi JL
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database.
    Nagasu H; Yano Y; Kanegae H; Heerspink HJL; Nangaku M; Hirakawa Y; Sugawara Y; Nakagawa N; Tani Y; Wada J; Sugiyama H; Tsuruya K; Nakano T; Maruyama S; Wada T; Yamagata K; Narita I; Tamura K; Yanagita M; Terada Y; Shigematsu T; Sofue T; Ito T; Okada H; Nakashima N; Kataoka H; Ohe K; Okada M; Itano S; Nishiyama A; Kanda E; Ueki K; Kashihara N
    Diabetes Care; 2021 Nov; 44(11):2542-2551. PubMed ID: 34593566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE.
    O'Hara DV; Neuen BL; Jardine MJ
    J Nephrol; 2020 Oct; 33(5):977-983. PubMed ID: 32725496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease.
    Khater J; Malakouti S; Khoury AE; Cortese B
    J Cardiovasc Med (Hagerstown); 2024 Apr; 25(4):247-258. PubMed ID: 38305141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study.
    Chan GC; Ng JK; Chow KM; Szeto CC
    Diabetes Res Clin Pract; 2023 Jan; 195():110200. PubMed ID: 36481225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease.
    Shivakumar O; Sattar N; Wheeler DC
    Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i43-i47. PubMed ID: 32003831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
    Herrington WG; Savarese G; Haynes R; Marx N; Mellbin L; Lund LH; Dendale P; Seferovic P; Rosano G; Staplin N; Baigent C; Cosentino F
    Eur J Heart Fail; 2021 Aug; 23(8):1260-1275. PubMed ID: 34184823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors.
    Chan CG; Stewart R
    N Z Med J; 2022 Aug; 135(1560):99-104. PubMed ID: 35999803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.